MENU
+Compare
IMAB
Stock ticker: NASDAQ
AS OF
Apr 17 closing price
Price
$0.85
Change
+$0.01 (+1.19%)
Capitalization
68.88M

IMAB I-MAB Forecast, Technical & Fundamental Analysis

I-MAB is a clinical-stage biotech company... Show more

IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IMAB with price predictions
Apr 17, 2025

IMAB's Indicator enters downward trend

The Aroon Indicator for IMAB entered a downward trend on April 11, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 303 similar instances where the Aroon Indicator formed such a pattern. In of the 303 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 42 cases where IMAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

IMAB moved below its 50-day moving average on April 16, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMAB broke above its upper Bollinger Band on April 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMAB's RSI Indicator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 14, 2025. You may want to consider a long position or call options on IMAB as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IMAB just turned positive on April 14, 2025. Looking at past instances where IMAB's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IMAB advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.342) is normal, around the industry mean (13.444). P/E Ratio (0.000) is within average values for comparable stocks, (62.833). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.754). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (16.978) is also within normal values, averaging (250.783).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IMAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

IMAB is expected to report earnings to rise 132.55% to -12 cents per share on November 29

I-MAB IMAB Stock Earnings Reports
Q3'23
Est.
$-0.13
Q4'24
Est.
$-0.06
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.22
Q1'24
Est.
$-0.22
The last earnings report on April 03 showed earnings per share of -5 cents, beating the estimate of -5 cents. With 33.91K shares outstanding, the current market capitalization sits at 68.88M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
555 West Haiyang Road
Phone
+86 2160578000
Employees
318
Web
https://www.i-mabbiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla
BTC.X84450.805000-444.945300
-0.52%
Bitcoin cryptocurrency

IMAB and Stocks

Correlation & Price change

A.I.dvisor tells us that IMAB and CTMX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMAB and CTMX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
+0.46%
CTMX - IMAB
32%
Poorly correlated
+4.18%
RPRX - IMAB
31%
Poorly correlated
+1.27%
IRD - IMAB
28%
Poorly correlated
+3.37%
TPST - IMAB
28%
Poorly correlated
+0.41%
AVTE - IMAB
27%
Poorly correlated
+2.61%
More